Examining the role of exosomes released by platelets
Official title: Characterization of Exosomes Platelets-released
Run by Centro Cardiologico Monzino · NCT06298682 · Data updated 2026-11-12
This study is testing how tiny particles released by platelets in the blood might help us understand heart disease better and see if certain medications affect them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years to 60 Years |
| Sex | All |
| Enrollment | 175 (estimated) |
| Sponsor | Centro Cardiologico Monzino Academic / other |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | July 8, 2021 |
| Main results expected | July 7, 2026 |
| Study ends | July 7, 2027 |
| Registry record updated | March 12, 2024 |
| Trial ID | NCT06298682 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are healthy individuals without known pathologies.
✕Probably not a fit
Patients with a history of various diseases, including gastrointestinal, hepatic, urogenital, hematological, immunological, renal, metabolic, respiratory, cancer, cardiovascular diseases, or those with permanent organ damage, will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to characterize platelet-derived extracellular vesicles (exosomes) and their role in cardiovascular disease. It will enroll 54 subjects from Centro Cardiologico Monzino IRCCS and analyze blood samples to assess the impact of antiplatelet agents on exosome release and content. The study will collect biographical and anthropomorphic data alongside fasting blood samples for haematochemical analyses. The goal is to enhance understanding of exosomes as potential biomarkers for clinical diagnostics.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic tools for cardiovascular diseases through the identification of exosome biomarkers.
How similar studies have gone: While the role of exosomes in cardiovascular disease is an emerging field, this specific approach to characterizing platelet-derived exosomes is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * subjects without known pathologies Exclusion Criteria: * individuals with gastrointestinal diseases, * individuals with history of hepatic diseases, * individuals with history of urogenital diseases, * individuals with history of hematological diseases, * individuals with history of immunological diseases, * individuals with history of renal diseases, * individuals with history of metabolic diseases * individuals with history of respiratory diseases * individuals with history of cancer * individuals with history of cardiovascular disease * individuals having permanent organ damage * individuals with major trauma in the last 6 months prior to enrollment * individuals with surgery in the last 6 months prior to enrollment * individuals taking medication in the 15 days prior to enrolment.
Where it's running
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy Recruiting
Study contacts
- Study coordinator: Silvia S Barbieri, PhD
- Email: silvia.barbieri@ccfm.it
- Phone: 0258002021
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating platelet activation in patients with heart support devices
This study is testing how well platelets work in patients with severe heart failure who are getting or have received a heart support device to see if it can help prevent complications.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Automated Echocardiography Measurements Using Deep-Learning Software
This study tests whether US2.AI can automatically measure heart structure and function from standard echocardiograms as accurately as expert clinicians in adults.
-
Insights from the FAST-TRACK CABG Experience in Complex Multivessel Disease
This study tests whether imaging-derived markers from CCTA and FFRCT can predict symptom relief and major cardiovascular outcomes after CCTA-guided CABG in people with complex multivessel disease.
-
What happens to the tricuspid valve in atrial fibrillation patients without strong valve leakage
This study looks at how the tricuspid valve changes over a year in people with atrial fibrillation who don’t have significant valve leakage, using 3D heart imaging.
-
Mitral Valve Calcification Imaging with TrueVue 3D Light Rendering
This study tests how well three-dimensional transesophageal echocardiography with TrueVue transillumination detects mitral valve calcifications compared with CT in adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.